Transcranial Photobiomodulation For The Management Of Depression: Current Perspectives

Paula Askalsky1
Dan V Iosifescu1,2
1Department of Psychiatry, NYU Langone School of Medicine, New York, NY, USA; 2Clinical Research Division, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY, USA

Abstract: Major depressive disorder (MDD) is a prevalent condition associated with high rates of disability, as well as suicidal ideation and behavior. Current treatments for MDD have significant limitations in efficacy and side effect burden. FDA-approved devices for MDD are burdensome (due to repeated in-office procedures) and are most suitable for severely ill subjects. There is a critical need for device-based treatments in MDD that are efficacious, well-tolerated, and easy to use. In this paper, we review a novel neuromodulation strategy, transcranial photobiomodulation (t-PBM) with near-infrared light (NIR). The scope of our review includes the known biological mechanisms of t-PBM, as well as its efficacy in animal models of depression and in patients with MDD. Theoretically, t-PBM penetrates into the cerebral cortex, stimulating the mitochondrial respiratory chain, and also significantly increases cerebral blood flow. Animal and human studies, using a variety of t-PBM settings and experimental models, suggest that t-PBM may have significant efficacy and good tolerability in MDD. In aggregate, these data support the need for large confirmatory studies for t-PBM as a novel, likely safe, and easy-to-administer antidepressant treatment.

Keywords: low-level light therapy, photobiomodulation, near infrared radiation, major depressive disorder, depression

Introduction

Major depressive disorder (MDD) is prevalent (affecting 16.2% of the US population, lifetime) and disabling, being among the leading causes of years lived with disability worldwide.1,2 Existing antidepressants have burdensome side effects and are only partially effective; more than one-third of MDD patients do not achieve remission after several adequate antidepressant trials, and relapses are frequent.3 One option for individuals who do not respond to or tolerate antidepressant medications are neuromodulation strategies, which include the FDA-approved electroconvulsive therapy (ECT), transcranial magnetic stimulation (rTMS), and vagus nerve stimulation (VNS). Other neuromodulation options, such as transcranial direct current stimulation (tDCS), magnetic seizure therapy (MST), and deep brain stimulation (DBS), remain experimental.4 Despite their efficacy, FDA-approved neurostimulation strategies are complex procedures requiring multiple visits (ECT and rTMS), anesthesia (ECT), or surgical implantation (VNS). There is a clear need for a safe and effective neuromodulation strategy that may be well tolerated and potentially used by patients at home.

Transcranial photobiomodulation (t-PBM) is a novel form of neuromodulation, based on non-retinal exposure to light at specific wavelengths. t-PBM with near-infrared radiation (NIR) has yielded promising early results for the treatment of...
neuropsychiatric disorders.\textsuperscript{5} t-PBM has a low cost, good safety profile, and it is easy to self-administer. Therefore, it has the potential to become widely accessible.

We have reviewed in this paper the known biological mechanisms of t-PBM and its clinical efficacy data in MDD.

\textbf{Transcranial Transmission Of NIR And Red Light}

Before delving into the mechanics and potential effects of PBM, it is important to consider whether t-PBM can even reach the brain. After all, the light must pass through various layers of tissue and the skull, before reaching the cortex. An early study performed in a small cohort of patients undergoing neurosurgery postulated that out of all the layers between the scalp and cerebral tissue, the skull was the greatest impediment of light transmission.\textsuperscript{6} Others have pointed out that even 2mm of hair can absorb or reflect approximately 98% of NIR energy from a 10W laser.\textsuperscript{7}

Thankfully, several studies have tried to answer this question directly. Jagdeo et al (2012) measured the transmission of NIR and red light with a piece of human cadaveric skull and overlying tissue. They used a commercial LED device used in multiple clinical studies, the Omnilux New-U.\textsuperscript{8} They found that compared to red light (wavelength 633nm), NIR light (830nm) more appreciably penetrated the skull and soft tissue. Still, only 0.9–2.1% of NIR light penetrated through the cadaver skull and intact soft tissue in the frontal or temporal regions. Lapchak et al (2015) used a Class IV laser with a surface power density of 700mW/cm\textsuperscript{2} and found that more than 95% of the NIR light transmission was attenuated when applied to human cadaveric skulls.\textsuperscript{9} In a later study using a human cadaveric model, 808nm light, delivered by a transcranial laser system, penetrated to a brain depth of 40–50mm.\textsuperscript{10}

Some have looked at the effect of wavelength, power, and delivery mode on transmission, as well. In the same study by Tedford et al (2015) mentioned earlier, the authors found that out of three tested wavelengths ranging from 660 to 940nm, 808nm showed superior penetration.\textsuperscript{10} Another study looking at the penetration depths of 675nm, 780nm, and 835nm in various human tissues, including post-mortem brain tissue, also argued that greater transmission was achieved with longer wavelengths.\textsuperscript{11} Henderson and Morries (2015) performed ex vivo studies of NIR penetration through 3cm of lamb skull, tissue, and brain.\textsuperscript{12} Two LED NIR emitters with lower energy (50 and 200mW) did not penetrate the 3cm of tissue. On the other hand, devices with power in the range 6–15W did penetrate the tissue. Further, the same 15W device reached variable depths, depending on wavelength used. With the 810nm setting, 2.9% of the power density was delivered to the cortex and with the 980nm setting, only 1.22% was delivered. This observation is consistent with the data presented earlier that transmission of t-PBM is likely dependent on wavelength and that 810nm may be preferable for this reason. Lastly, they reported that pulsed emission settings (10Hz) led to higher energy delivery, as seen in 2 of the 3 tested settings. However, those two settings also included longer wavelengths (980nm), while the third setting only had a wavelength of 810nm. Therefore, it is unclear if the increased energy delivery is due to pulsing alone or an interaction between wavelength and pulsing.

Two computation studies have also looked at ways to enhance penetration of light. Yue et al (2015) proposed using a multiunit emitter array, evenly distributed across the scalp, to take advantage of photon scattering properties in the brain.\textsuperscript{13} Using Monte Carlo simulations in a human head model to test this idea, they demonstrated that the multiunit emitter enhanced photon flux and improved uniformity of distribution. While this model is theoretically interesting, these results are likely not necessarily applicable to in vivo models, since little energy is absorbed through the skull and overlying tissues. Therefore, the photo-scattering of incident light described above is unlikely to be seen in the human brain. Another study looked at whether transcranial and transsphenoidal administration of red and NIR light could reach deep brain structures, and specifically, the substantia nigra.\textsuperscript{14} Both a cadaveric model and the Monte Carlo method were used. Ultimately, NIR light was felt to be more effective for transmission to the substantia nigra, due to less absorption and scattering; this was particularly true when the light was delivered via the sphenoid sinus.

Overall, studying the transcranial penetration of NIR and red light has several challenges. For one, only cadaveric models for humans can be used. Therefore, it is difficult to directly test the effect of blood flow and hydration status on attenuation of light. Though we are currently limited in our ability to study the full depths of t-PBM’s reach in the in vivo human brain, there are several measures that we can take to enhance penetration. Based on the data presented above, using wavelengths in the range of 808–835nm, laser devices, higher power densities, and pulsed parameters will likely increase efficacy. Practically speaking, we may also be limited to t-PBM application to the prefrontal cortex,
unless patients are willing to shave their hair for the duration of treatment (which would be required to target other cortical brain areas). Further, while LED devices are less expensive and potentially more appealing to the average consumer, their clinical effectiveness is in question. Hopefully, future clinical studies utilize tools such as blood flow changes (measured by BOLD signal on fMRI) and bioenergetic metabolite changes (measured with magnetic resonance spectroscopy) to understand the depths of cortical effects in-vivo in humans.

Proposed Mechanisms Of t-PBM Mitochondrial Function And Association With Depressive Symptoms

To understand the proposed mechanisms of t-PBM, we must first understand some basic principles of the mitochondria and the production of ATP. Oxidative phosphorylation, which takes place in the inner mitochondrial membrane, is one of the mechanisms by which ATP is generated. Substrates donate electrons to individual complexes (Complexes I-IV) and mobile components of the electron transport chain (ETC), such as coenzyme Q and cytochrome C oxidase (CCO), move electrons between the protein complexes. A proton gradient is established along the way, creating an electrochemical force. Ultimately, the energy stored by the proton gradient is captured by complex V and used to generate ATP.

Multiple animal and human studies have found mitochondrial differences in depression, with specific changes seen in respiration and generation of ATP. In a rat model of depression, complexes I, III, and IV of the ETC were inhibited in the cerebral cortex and cerebellum. Changes in cytochrome oxidase activity have also been implicated in depression. Phosphorus magnetic resonance spectroscopy (31P-MRS) allows in vivo measurements of energy-rich compounds resulting from mitochondrial activity. For example, β-NTP is used to estimate the level of ATP. Phosphocreatine transfers high-energy phosphate groups to ATP, making it another useful marker. Using 31P-MRS, Harper et al (2016) found that decreased β-NTP levels correlated with executive dysfunction in depressed geriatric patients. Similarly, other 31P-MRS studies reported lower levels of β-NTP and compensatory higher levels of phosphocreatine (PCr) in non-geriatric adults with MDD. In both studies, these abnormalities related to mitochondrial function were associated with clinical response to antidepressants.

Changes in glucose metabolism have also been described in FDG PET studies in MDD. For example, MDD patients were shown to have increased mean glucose metabolism in the lateral orbital cortex, ventrolateral prefrontal cortex, left amygdala, and posterior cingulate cortex, as well as decreased metabolism in the subgenual ACC and dorsal medial/dorsal anterolateral PFC. Following treatment, metabolism in the left amygdala and left subgenual ACC decreased in these subjects. Another FDG PET study of MDD participants post-fluoxetine treatment showed that treatment responders had decreased glucose metabolism in limbic and striatal areas, as well as increased metabolism in brainstem and dorsal cortical regions.

Changes in mitochondrial respiration in depression have been found outside of the central nervous system as well. Peripheral blood mononuclear cells of depressed patients were shown to have significantly impaired mitochondrial function. In fact, greater mitochondrial dysfunction correlated with severity of neurovegetative symptoms, including fatigue and poor concentration. Similarly, Hroudova et al (2013) found that the respiratory rate and maximal capacity of the ETC were significantly decreased in platelets of depressed patients. Muscle biopsy samples from depressed patients with physical symptoms had a decreased rate of ATP production and more frequent mitochondrial DNA deletions than controls. Treatment studies have yielded further evidence for the mitochondrial hypothesis of depression. After 21 days of treatment with desipramine and fluoxetine, somatic mitochondria in the rat frontal cortex had enhanced energy metabolism (though there was decreased energy production in synaptic mitochondria).

Mitochondrial Effects Of PBM

Mitochondria are the main site of physiologic changes related to t-PBM. The cascade starts with CCO, which is a chromophore, a photoacceptor, and the terminal enzyme of the electron transport chain. t-PBM has been found to specifically increase CCO activity and expression. Studies have also shown increases in complex II, II, III, and IV activity, as well as upregulation of gene coding for subunits of complex I, complex IV, and ATP synthase. Additionally, PBM of complexes II and III still occurs with higher fluence lasers, despite previous concerns that the increased level of stimulation would be too strong. Though the focus has primarily been on enhanced effects of mitochondrial function, some have suggested that pulsed t-PBM may also increase the number of isolated mitochondria.
Further, low-level laser therapy has been shown to increase levels of ATP, the rate of oxygen consumption, and cerebral oxygenation. In a mouse model, low-intensity NIR was able to ameliorate reduction of ATP that was previously induced by oxygen-glucose deprivation. Another study using two different depression mouse models showed increased ATP biosynthesis and mitochondrial complex IV expression following t-PBM in the prefrontal cortex specifically. While the time-to-effect of metabolic changes is unclear, Ferraresi et al (2015) suggest that the ATP levels are highest about six hours following treatment. On the other hand, another group found that bioenergetic changes were noticeable only after two weeks of repeated treatments.

Effects Of Specific Wavelengths Of PBM On Mitochondria

Though t-PBM with red and NIR light can include wavelengths from 600 to 1070nm, specific wavelengths have been directly linked to mitochondrial activity. 810nm NIR activates CCO, increases mitochondrial oxygen consumption, and leads to higher levels of ATP. Further, a mouse model of TBI showed improvement in wavelength-dependent fashion - namely, 660nm and 810nm treatments led to improvement, while 730 and 980nm treatments did not. Subsequent analyses of 810nm and 980nm wavelengths propose that 810nm acts on CCO, but that 980nm works on temperature-gated calcium ion channels.

Blood Flow And t-PBM

Several studies have looked at t-PBM’s ability to alter regional cerebral blood flow (CBF). In one animal study, NIR laser irradiation increased cerebral blood flow by 30%. Additionally, repeated NIR LED irradiation to the forehead increased regional CBF by 20% in a patient in persistent vegetative state. In a larger study of 25 healthy, elderly women, Salgado et al (2015) found that transcranial LED therapy in the red-wavelength spectrum also increased local CBF. Lastly, Dias et al (2012) showed dose-dependent modulation of vascular endothelial growth factor (VEGF), which stimulates angiogenesis, and VEGF Receptor-2 (VEGFR-2) in rat masseter muscles, following 10 laser irradiations with 780nm light.

Nitric Oxide

Nitric oxide (NO) is an endogenous vasodilator that plays an important role in normal circulation. NO can also inhibit respiration by binding to cytochrome oxidase and displacing oxygen. Differences in nitric oxide levels have been seen in depressed versus non-depressed populations. Additionally, low-light level therapy has been shown to alter nitric oxide activity and may be a key in understanding the downstream effects of the treatment. Zhang et al (2009) showed that nitric oxide was directly implicated in the protective effects of NIR in an animal model of cardiomyocyte injury. In another study, NIR irradiation increased both NO concentration and local cerebral blood flow in mice. When nitric oxide synthase was blocked, cerebral blood flow and NO failed to increase. While this was used as evidence that NO played a role in regional CBF changes after irradiation, others have suggested that the effects of nitric oxide may be independent of nitric oxide synthase. Lastly, it has been proposed that PBM may work by releasing NO from CCO and therefore disinhibiting mitochondrial respiration.

Reactive Oxygen Species (ROS) And Neuroinflammation

In 2007, Sarandol et al found that red blood cells (RBCs) were more susceptible to oxidation in depressed patients, compared to controls. Further, they saw that superoxide dismutase (SOD) activity was significantly higher in depressed patients and that the level of SOD activity positively correlated with disease severity. By the same token, PBM has been shown to effect oxidative stress and inflammation. An earlier study suggested that in vitro use of NIR could potentially protect the RBC membrane. Huang et al (2013) found that t-PBM actually increased ROS in normal neurons, but reduced ROS in oxidatively stressed neurons. Going even further, Salehpour et al (2018) demonstrated that NIR t-PBM could affect behavioral outcomes and oxidative stress in a mouse model. They used sleep deprivation to induce oxidative stress in the hippocampus and then looked at effects on spatial and episodic-like memories. When NIR was applied transcranially, antioxidants were enhanced in the hippocampus and cognitive impairment was ameliorated. In a mouse depression model, PBM decreased malondialdehyde levels and increased levels of antioxidants enzyme activity (i.e., GPx, SOD, TAC) in the prefrontal cortex and hippocampus. Additionally, t-PBM reduced pro-inflammatory cytokines.

Apoptosis Mechanisms

In addition to the downstream effects already explained, t-PBM may have a role in preventing apoptosis, resulting
in neuroprotection. In one study, apoptotic markers in the prefrontal cortex and hippocampus were elevated after five days of sub-chronic restraint stress. The authors found that t-PBM ameliorated the stress-induced pro-apoptotic response, as evidenced by a reduced Bax/Bcl-2 and cytosolic/mitochondrial CCO ratios. Other studies have similarly demonstrated a reduction in the Bax/Bcl-2 ratio following t-PBM. Additionally, NIR has been shown to protect against neuronal loss in the setting of ischemic insult.

Some authors suggest that t-PBM can even help with neurogenesis. Tanka et al. (2011) found that acute or chronic exposure to infrared radiation could increase the number of BrdU-positive cells in CA1 region of the hippocampus, suggesting increased proliferation. Similarly, exposure to a 810nm laser following controlled cortical impact in a mouse model of TBI led to significantly higher levels of brain-derived neurotrophic factors (BDNF) in some sub-regions of the hippocampus. In an animal model of stroke, t-PBM not only decreased the infarct size, but it also increased levels of biomarkers indicative of cell proliferation.

**Pre-Clinical Trials Of t-PBM Treatment For Depression (See Table 1)**

One of the earliest studies compared acute and chronic exposure of infrared radiation against controls. Acutely exposed rats underwent infrared treatment for one session, while chronically exposed rats completed 10 sessions. During each treatment, the animals’ heads were immobilized and irradiated for 3 mins (highest emissivity values within 0.6–1.6μm, maximal irradiation intensity of 1800–2200mW). Twenty-four hours after the last irradiation treatment, the rats were subjected to behavioral testing, including the elevated plus maze, the light/dark test, and the forced swim test. Researchers found that chronic exposure of infrared radiation significantly and consistently ameliorated anxiety and depression-related behavior, compared to acutely exposed rats and controls. In addition, they found that both acute and chronic exposure to the treatment condition significantly increased the number of BrdU-positive cells in CA1 of the hippocampus, indicating neurogenesis. Since both acute and chronic exposures led to hippocampal neurogenesis, this finding could not explain the differences in behavioral outcomes between the two groups.

Xu et al. (2017) also looked at the effects of chronic irradiation. (t-PBM) of the cerebral cortex was performed for 30 mins daily, for a total of 28 days. A diode laser, with a wavelength of 808nm, was used to deliver a power output density of 23mW/cm² to the scalp. After 14 days of treatment, the t-PBM treated mice showed a significantly lower immobility time in the forced swim test and the tail suspension test (two behavioral assessments of depressive behavior), compared to sham-treated mice. Interestingly, this attenuation effect was stable after the 21st day of treatment. In an attempt to elucidate the underlying mechanism behind t-PBM’s therapeutic effect, they also measured the mitochondrial complex I-IV content and level of ATP biosynthesis in the prefrontal cortex, hippocampus, and hypothalamus. Following the full course of treatment, ATP biosynthesis and mitochondrial complex IV both significantly increased in the prefrontal cortex only. Taken together, this paper suggests that t-PBM reduces depressive symptoms via increased ATP and mitochondrial complex IV levels in the prefrontal cortex.

In another study using low-level infrared laser irradiation, several different power settings were tested to assess alterations in depressive behavior by dose. First, 80, 200, and 400 mW, all on continuous wave mode, were compared in their ability to improve mobility during the forced swim test in normal rats. Irradiation was performed daily for 1 week during this initial phase. A diode (GaAlAs) laser (Lasotronic Inc., Zug, Switzerland) with a wavelength of 804nm was used to irradiate the entire cortex via six different points, for 1 min per point. For the 3 powers listed above, the power densities were 0.64, 1.60, and 3.18W/cm², respectively, and the three energy doses were 4.8, 12, and 24J/point. After 7 days of treatment, normal rats treated with the 400mW laser showed more depressive symptoms (significant increase in immobility, as well as decrease in both swimming and climbing during the forced swim test) compared to controls. On the other hand, those treated with 80 mW had significantly decreased immobility time, increased swimming, and increased climbing behavior. In the second phase of the study, rats were given reserpine to create an animal model of depression. A subgroup of the reserpinized rats were irradiated daily for 7 days, using the 80mW power setting. Treatment with 80mW was able to reverse the depression-like behaviors of reserpinized rats. Overall, these results show a biphasic response to irradiation, with higher power setting causing worsening depression-like behavior and lower power settings leading to amelioration of symptoms.
<table>
<thead>
<tr>
<th>Paper</th>
<th>Subjects</th>
<th>Device</th>
<th>Number Of Treatments</th>
<th>Area Irradiated</th>
<th>Wavelength</th>
<th>Pulsed Or Continuous</th>
<th>Irradiance</th>
<th>Fluence</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mohammed (2016)</td>
<td>Rats</td>
<td>Diode (GaAlAs) Laser (Lasotronic Inc., Zug, Switzerland)</td>
<td>Daily for 1 week</td>
<td>Six points arranged symmetrically to ensure irradiation of the entire cortex</td>
<td>804nm</td>
<td>Continuous</td>
<td>0.64, 1.60, and 3.18W/cm² for three assigned powers of laser</td>
<td>4.8, 12, and 24 j/cm² for three powers of laser</td>
<td>Treatment with lower power (80mW) reversed depressive effects of reserpine</td>
</tr>
<tr>
<td>Xu et al (2017)</td>
<td>Mice</td>
<td>Diode laser quipped with quartz-silica fiber (FU808AD500-BD10, Shenzhen Fuzhe Technology co., Ltd.)</td>
<td>30 min per day for 28 days</td>
<td>Cerebral cortex</td>
<td>808nm</td>
<td>Continuous</td>
<td>23mW/cm²</td>
<td>Not provided</td>
<td>t-PBM attenuated depression-like behaviors</td>
</tr>
<tr>
<td>Salehpour et al (2016)</td>
<td>Rats</td>
<td>Red and NIR probes derived by GaAlAs diode laser (Mustang 2000+, Moscow, Russia)</td>
<td>Four times a week for three weeks</td>
<td>Prefrontal region</td>
<td>630nm (Red), 810nm (NIR)</td>
<td>10-Hz, Pulsed</td>
<td>89mW/cm² (Red), 562mW/cm² (NIR)</td>
<td>1.18 ± 0.01J/cm² per each session, about 14.4J/cm² over entire treatments</td>
<td>NIR and citalopram significantly decreased depression-like behaviors, but the red wavelength condition did not</td>
</tr>
<tr>
<td>Ando et al (2011)</td>
<td>Mice</td>
<td>Diode laser (DioDent Micro 810, HOYA ConBio, Fremont, CA) equipped with quartz-silica fiber</td>
<td>Single 12-min exposure of transcranial t-PBM, 4 hrs post TBI</td>
<td>Left frontal-parietal cortex</td>
<td>810 ± 2nm</td>
<td>Continuous, 10- Hz Pulsed, or 100-Hz Pulsed</td>
<td>Average = 50mW/cm², Peak for pulsed modes = 100mW/cm²</td>
<td>36J/cm²</td>
<td>t-PBM had an antidepressant effect 4 weeks after treatment</td>
</tr>
<tr>
<td>Tanaka et al (2011)</td>
<td>Rats</td>
<td>Infrared emitter</td>
<td>Acute exposure group = one session for 3 mins, Chronic exposure group = 10 sessions for 3 mins daily</td>
<td>Head</td>
<td>Emitter had highest emissivity values within 600–1600nm</td>
<td>Not provided</td>
<td>Calculated maximal irradiation intensity of 1800–2200mW</td>
<td>Not provided</td>
<td>Depressive-like behavior significantly improved in chronically exposed group</td>
</tr>
<tr>
<td>Wu et al (2012)</td>
<td>Rats</td>
<td>Diode laser</td>
<td>Three times a week for three weeks, 2-min irradiation time for each treatment</td>
<td>Midline of the dorsal surface of the head, between the eyes and ears</td>
<td>810nm</td>
<td>100-Hz, Pulsed</td>
<td>Average = 15mW/cm²</td>
<td>120J/cm²</td>
<td>Depressive-like behavior significantly decreased in the fluoxetine and transcranial light therapy groups</td>
</tr>
</tbody>
</table>
Another study compared two wavelengths of laser light against citalopram in a rat depression model. After undergoing chronic mild stress procedures over 4 weeks to induce a depressive phenotype, rats were divided into a stress group, a citalopram group, a red laser-group (630 nm), and an NIR laser group (810 nm). All t-PBM treatments were performed over the prefrontal region, using a GaAlAs diode laser (Mustang 2000, Moscow, Russia). The laser was set to 10-Hz pulsed wave with power densities of 89mW/cm² for red beams and 562mW/cm² for NIR beams. Both treatment settings had an average energy density of 1.18±0.01J/cm² per each session. Following 3 weeks of treatment, rats in the NIR and citalopram treatment groups showed significantly less immobility and higher swimming times than the stress group. Interestingly, the red treatment group did not show a significant effect. On the other hand, only citalopram and red laser treatment affected anxiety-like behavior during the elevated plus maze task. Further, red laser and citalopram treatments lowered blood cortisol, while all treatment modalities lowered blood glucose levels.

In a similar study, Salehpour et al (2017) used rats who had undergone a standard chronic mild stress procedure to create an animal model of depression. Following the 4-week procedure, rats were randomly divided to receive NIR transcranial laser therapy and others were assigned to receive citalopram. Other animals acted as controls. Laser therapy sessions consisted of irradiation over the prefrontal region with an 810nm NIR probe derived by GaAlAs diode laser (Mustang 2000+, Russia; output power of 240±5mW, 10Hz pulsed wave, average energy density of 1.2J/cm² per each treatment). After a series of 12 treatments, rats underwent testing with the forced swim test to assess depressive behaviors. Both NIR therapy and citalopram significantly increased swim time and decreased immobility compared to the depressive group. Curiously, only citalopram significantly decreased blood cortisol levels.

Wu et al (2012) also tested pulsed light and an antidepressant in a rat model of depression. After undergoing various mild stressors for 5 weeks, rats assigned to the drug group received daily injections of fluoxetine and those assigned to the t-PBM underwent treatment 3 times a week for 2 mins each session. All treatment paradigms lasted for 3 weeks, with concurrent, ongoing chronic mild stress. t-PBM was delivered to dorsal surface of the head, between the eyes and ears, using an 810nm, with pulsed parameters of 100Hz and an average power density of

<table>
<thead>
<tr>
<th>Study</th>
<th>Laser Parameters</th>
<th>Treatment Settings</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salehpour et al (2017)</td>
<td>810nm 10-Hz, Pulsed</td>
<td>Output power of 240±5mW, 10Hz pulsed wave</td>
<td>Lowered blood cortisol</td>
</tr>
<tr>
<td>Wu et al (2012)</td>
<td>810nm 10-Hz, Pulsed</td>
<td>Average energy density of 1.2J/cm²</td>
<td>Lowered blood cortisol</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study</th>
<th>Laser Parameters</th>
<th>Treatment Settings</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salehpour et al (2017)</td>
<td>810nm 10-Hz, Pulsed</td>
<td>Output power of 240±5mW, 10Hz pulsed wave</td>
<td>Lowered blood cortisol</td>
</tr>
<tr>
<td>Wu et al (2012)</td>
<td>810nm 10-Hz, Pulsed</td>
<td>Average energy density of 1.2J/cm²</td>
<td>Lowered blood cortisol</td>
</tr>
</tbody>
</table>
15mW/cm². At the completion of 3 weeks of treatment, both the fluoxetine and t-PBM groups had significantly higher swimming and lower immobility counts than the untreated group. Additionally, there was no significant difference between the fluoxetine group and TLT group.

More recently, Salehpour et al (2018) studied the effects of PBM and coenzyme Q10, an essential cofactor in the electron transport chain.15,65 NIR t-PBM and coenzyme Q10, alone or in combination, were given for 5 days in a mouse model of depression. During t-PBM sessions, an NIR GaA1As laser (Thor Photomedicine, Chesham, UK), with a wavelength of 810nm and a 10-Hz pulsed wave frequency, was used to irradiate the dorsal surface between the eyes and ears. Sessions lasted 5s and delivered a dose of 33.3J/cm². Irradiance was 6.66W/cm². Following a course of treatment, behavioral testing was performed. During the forced swim test, both CoQ10 and t-PBM significantly reduced immobility time on their own. However, the combination of the two treatment modalities lowered the immobility time even further. CoQ10 and t-PBM, both alone and in combination, also significantly reduced immobility time, as tested by the tail suspension test.

Another study directly compared the therapeutic benefits of pulsed vs continuous irradiation, but in a mouse model of TBI.76 Four-hours post TBI, three groups of mice were given a single irradiation treatment for a total of 12 mins. Mice were assigned to treatment on either continuous wave, 10-Hz, or 100-Hz wave settings. Laser treatments were conducted using a 810-nm Ga-Al-As diode laser (DioDent Micro 810, HOYA ConBio, Fremont, CA), with a total fluence of 36 J/cm². The device was positioned over the left frontoparietal cortex (the region of the induced lesion) and delivered a power density of 50mW/cm². Behavioral testing, using the forced swim test and tail suspension test, was performed 1 day after TBI, and again at 4 weeks. After 28 days, mice treated with 10-Hz pulsed wave laser had significantly increased mobility in the forced swim test, compared to untreated mice. In the tail suspension test, both pulsed wave laser-treated groups had significantly decreased immobility compared to untreated mice. There was also a significant difference between the 10-Hz group and the continuous wave group.

In conclusion, all the animal studies reviewed used a transcranial t-PBM approach, but their methodologies varied greatly. For example, some studies used chronic, while other used acute exposure to t-PBM. They also used different animal models of depression or TBI and different settings for the NIR radiation (power, wavelength, areas stimulated). As such, it is difficult to compare or aggregate the results. Despite the limitations, these studies provide significant support for the potential antidepressant effect of t-PBM.

Clinical Trials Of t-PBM Treatment For Depression (See Table 2)

In an early study, 10 patients with major depression (9 with co-morbid anxiety, 7 with past history of substance abuse, 3 with co-morbid PTSD) received four 4-min NIR treatments in random order at EEG sites F3 and F4, as well as placebo treatments at the same sites, using an LED array (Marubeni America Corp, Santa Clara, CA).77 The study found significantly improved HAM-D scores at 2 weeks, with attenuation of effect at 4 weeks. At the 2-week follow-up point, 10 patients were “improvers” (at least a 20% reduction in HAM-D), 4 out of 10 patients were “responders” (>50% reduction in HAM-D) and 4 out of the 10 patients achieved “remission,” (HAM-D <8). By 4 weeks, only 5 out of 10 patients were “improvers,” 2 were “responders,” and none were in “remission”. These results suggest that one set of treatments was enough to yield significant improvement in a relatively short timeframe (2 weeks), but was not enough to sustain robust effects after 1 month. Parallel results were also found for changes on the HAM-A, a measure of anxiety.

Another study had a slightly longer follow-up period. In a pilot, open-protocol study of 11 participants with chronic, mild TBIs, 5 of the 10 participants were found to have moderate or severe depression scores on the Beck Depression Inventory (4 had PCL-C scores suggestive of PTSD, 3 had scores indicative of PTSD plus Depression).78 Each participant underwent 18 treatments (3 times/week) over the course of 6 weeks. During each session, an LED cluster head was applied for 10 mins to 11 scalp placements (midline from front-to-back hairline; bilaterally on frontal, parietal, and temporal areas) and one LED cluster was applied to the sole of the foot. In this paradigm, LED Console Units with three LED cluster heads each, were used (MedX Health, Model 1100, Toronto). Every LED cluster head contained 9 red diodes with wavelength of 633nm and 52 NIR diodes with wavelength of 870nm, as well as 22.2mW/cm² power density and energy density of 13J/cm². Of the 5 patients with BDI scores suggesting...
Table 2: All available clinical research studies and case reports that utilized transcranial photobiomodulation, with wavelengths in the red and/or near-infrared range, for treatment of depression.

<table>
<thead>
<tr>
<th>Paper</th>
<th>Subjects</th>
<th>Design</th>
<th>Device</th>
<th>Number of Treatments</th>
<th>Area Irradiated</th>
<th>Wavelength</th>
<th>Pulsed or Continuous</th>
<th>Irradiance</th>
<th>Fluence</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cassano et al (2018)</td>
<td>13 MDD completers</td>
<td>Randomized, double-blind, sham controlled, pilot trial</td>
<td>Omnilux New U light emitting diode (LED) by Photomedex, Inc., Montgomeryville, PA</td>
<td>Twice a week for 8 weeks; sessions 25–30 mins</td>
<td>Dorsolateral prefrontal cortex, bilateral</td>
<td>823 nm</td>
<td>Continuous</td>
<td>36.2 mW/cm²</td>
<td>Up to 65.2 J/cm²</td>
<td>NIR increased mean change in Ham-D scores</td>
</tr>
<tr>
<td>Cassano et al (2015)</td>
<td>4 MDD completers</td>
<td>Pilot, open, proof of concept, prospective, double-blind, randomized study, crossover design</td>
<td>NeuroThera, continuously emitting GaAlAs laser, manufactured by PhotoThera Inc.</td>
<td>Twice a week for three weeks, 4 sites, 2 mins per site</td>
<td>Prefrontal cortex</td>
<td>808 ± 10 nm</td>
<td>Continuous</td>
<td>70 mW/cm²</td>
<td>84 J/cm²</td>
<td>50% Remission of MDD at weeks 6–7 (HAM-D ≤ 7)</td>
</tr>
<tr>
<td>Calderaro et al (2018)</td>
<td>1 MDD with anxious distress</td>
<td>Case report</td>
<td>i-PBM: Vielight light-emitting diode; t-PBM: Omnilux New U light emitting diode device (Photomedex Inc)</td>
<td>i-PBM: titrated up to twice daily; 25 mins per nostril; t-PBM (F3/F4): twice a week for 25 mins; t-PBM (Fp2): titrated up to 30 mins daily</td>
<td>i-PBM: proposed systemic effect; t-PBM: EEG sites F4, F3, or both on same day; later switched to Fp2</td>
<td>i-PBM: 810 nm; t-PBM: 830 nm</td>
<td>i-PBM: 10 Hz, pulsed; t-PBM: continuous</td>
<td>i-PBM: peak 14.2 mW/cm²; t-PBM: 33.2 mW/cm²</td>
<td>92% were responders (decrease of QIDS score ≥ 50% from baseline), 82% were remitters (QIDS ≤ 5)</td>
<td></td>
</tr>
<tr>
<td>Henderson and Morries (2017)</td>
<td>39 TBI patients who completed depression questionnaires</td>
<td>Open-label single-arm, proof-of-concept study</td>
<td>Class IV Lasers: LT1000 (LiteCare, Newark, DE, USA), Diowave 810 (Diowave, Riviera Beach, FL, USA), or Aspen Laser (Denver, CO, USA)</td>
<td>8–34 treatments, 30 mins per session</td>
<td>Overlying forehead and temporal regions bilaterally</td>
<td>810/980 nm</td>
<td>Continuous, sweeping</td>
<td>8–15 W</td>
<td>55–81 J/cm²</td>
<td>(Continued)</td>
</tr>
<tr>
<td>Paper</td>
<td>Subjects</td>
<td>Design</td>
<td>Device</td>
<td>Number Of Treatments</td>
<td>Area Irradiated</td>
<td>Wavelength</td>
<td>Pulsed Or Continuous</td>
<td>Irradiance</td>
<td>Fluence</td>
<td>Results</td>
</tr>
<tr>
<td>-------</td>
<td>----------</td>
<td>--------</td>
<td>--------</td>
<td>----------------------</td>
<td>-----------------</td>
<td>------------</td>
<td>---------------------</td>
<td>------------</td>
<td>---------</td>
<td>---------</td>
</tr>
<tr>
<td>Disner et al (2016)</td>
<td>51 adults with elevated symptoms of depression</td>
<td>Randomized, sham-controlled proof-of-principle study</td>
<td>CG-5000 high density laser (Cell Gen Therapeutics, Dallas, TX, USA)</td>
<td>Two sessions, 8 mins per session</td>
<td>Left or right forehead</td>
<td>1064nm</td>
<td>Continuous</td>
<td>250mW/cm²</td>
<td>60J/cm²</td>
<td>Right t-PBM yielded greater improvement in participants whose attention was responsive to attention bias modification</td>
</tr>
<tr>
<td>Henderson and Morries (2015)</td>
<td>1 TBI</td>
<td>Case Report</td>
<td>Class IV laser (Diowave 810, West Palm Beach, FL, USA)</td>
<td>20 treatments over the course of 4 months</td>
<td>Unknown</td>
<td>810nm</td>
<td>Unknown</td>
<td>Unknown</td>
<td>55 to 81J/cm²</td>
<td>Improved mood (self-report). SPECT: Significant change in left and right frontal cortices, as well as left and right temporal cortices</td>
</tr>
<tr>
<td>Morries et al (2015)</td>
<td>10 TBI who completed depression questionnaires</td>
<td>Retrospective Case Series</td>
<td>Class IV lasers: LT1000 (LiteCure, Newark, DE, USA) or Diowave 810 (Diowave, Riviera Beach, FL, USA)</td>
<td>10-20 treatments, 16-30 mins per session</td>
<td>Bilateral frontal, bilateral frontal + left temporal, bilateral frontal + bilateral temporal</td>
<td>810/980nm, one pt 810nm only</td>
<td>10-Hz Pulsed, scanning</td>
<td>Unknown</td>
<td>55 to 81J/cm²</td>
<td>BDI and QIDS-SR scores decreased from moderately depressed range to non-depressed range</td>
</tr>
<tr>
<td>Schiffer et al (2009)</td>
<td>10 MDD</td>
<td>Pilot Study</td>
<td>(LED) array (Marubeni America Corp, Santa Clara, CA)</td>
<td>One session consisting of Four 4-min treatments</td>
<td>Left forehead at F3 (over dorsolateral prefrontal cortex), Right forehead at F4</td>
<td>810nm</td>
<td>Unknown</td>
<td>250mW/cm²</td>
<td>60J/cm²</td>
<td>At 2-weeks post treatment, 4 out of 10 were responders (&gt;50% reduction in HAM-D), and 4 out of 10 were in remission (HAM-D &lt;8)</td>
</tr>
<tr>
<td>Naeser et al (2014)</td>
<td>11 mild TBI who completed BDI</td>
<td>Pilot, Open-Protocol Study, Case series</td>
<td>LED Console Units (MedX Health, Model 1100, Toronto), three LED cluster heads per unit</td>
<td>18 sessions over 6 weeks, 20 mins per session</td>
<td>11 scalp placements: midline from front-to-back hairline, and bilaterally on frontal, parietal, and temporal regions</td>
<td>633/870nm</td>
<td>Continuous</td>
<td>22.2mW/cm² per cluster head</td>
<td>13J/cm²</td>
<td>Trend towards significance for BDI scores 1 week post treatment</td>
</tr>
</tbody>
</table>
moderate-to-severe depression, 4 reported a reduced level of depression at 1 week post-LED treatment. Three of them continued to report reduction in symptoms at 1-month and 2-month follow-up visits. Similar to the prior study, 1 patient who had reported reduction in depression at 1 week and 1 month reverted back to severe depression at 2 months post-LED. These results suggest that a longer treatment course may lead to more sustained results.

In an open-pilot, proof of concept study, eight participants who met the criteria for at least moderate depression were enrolled. However, there were only four completers.79 Following a double-blind, sham-controlled model, subjects were randomized to 3 weeks of either NIR or sham, followed by crossover to 3 more weeks of the alternate treatment. Twice a week, subjects underwent treatment with a NeuroThera, continuously emitting GaAlAs-laser (PhotoThera Inc.) or the same device acting as a sham. Treatment involved irradiating the forehead bilaterally for 2 mins at 4 different sites. Parameters included a wavelength of 808 ± 10nm, irradiance of approximately 700mW/cm², and a fluence of 84J/cm². At the end of the study, 2 of the 4 participants achieved remission at weeks 6 and 7.

In a retrospective case series conducted by Morries et al. (2015), 10 patients with TBI (6 with co-morbid MDD) were enrolled to receive high-power NIR laser phototherapy with a Class IV laser.80 While the aim of this study was to target symptoms of TBI, over 90% of the patients complained of depression. Further, all subjects completed a baseline Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR) and seven completed the Beck Depression Inventory (BDI) before and after the course of treatment. Baseline scores fell in the moderate depression range. In this study, 6 participants received a single series of 10 treatments with the LT1000 Class IV laser (LiteCure, Newark, DE, USA; adjustable 10W NIR laser emitter with wavelengths of 810 and 980nm that can deliver continuous or pulsed light), 3 patients received a single series of 20 treatments with the LT1000 laser, and 1 patient underwent a series of 20 treatments with the Diowave 810-nm Class IV laser device (Diowave, Riviera Beach, FL, USA; up to 15W, wavelength of 810nm, can deliver continuous or pulsed NIR energy). Each treatment lasted 8–12 mins, depending on the subject, and fluence delivered to the skin ranged from 55 to 81J/cm². The areas targeted for treatment included the bilateral frontal and temporal regions. Following the above-stated interventions, QIDS-SR and BDI scores significantly decreased to the non-depressed range.

A subsequent open-label, single-arm, proof-of-concept trial of 39 patients with TBI and co-morbid depression tested the effects of Multi-Watt t-PBM on depression.81 Each participant received NIR light therapy, applied to the forehead and temporal regions bilaterally, for a total of 30 mins per session. Depending upon individual improvement, subjects got anywhere from 8 to 34 treatments. (12 participants underwent 12 or fewer treatments, 27 had 13 or more treatments). The time course of treatments also varied, with 15 participants undergoing all treatments under 8 weeks and 6 completing the course in 4 weeks or less. Another factor increasing the variability in the study includes use of three different Class IV lasers [LT1000 (LiteCure, Newark, DE, USA), Diowave 810 (Diowave, Riviera Beach, FL, USA), or Aspen Laser (Denver, CO, USA)]. The power ranged from 8 to 15W and fluence delivered to the skin of patients ranged from 55 to 81J/cm². To measure the effects of treatment on depressive symptoms, the Quick Inventory of Depression Symptomatology-Self Report (QIDS) was administered in all patients before and after. Overall, 92% of the patients responded to the treatment and 82% remitted from depression. Notably, patients who received ≥13 treatments had more significant results. Interestingly, some patients continued to show a response at 2, 6, 12, and 55 months follow-up points, indicating that the benefits were not transient.

The largest study to date had 45 total completers and data on 46 participants, all of whom came from a population of undergraduate students.82 The goal of this randomized, sham-controlled proof-of-principle study was to test the potential for transcranial laser stimulation to augment another type of intervention, attention bias modification (ABM). ABM is used to train individuals with a tendency towards negatively biased attention to shift their attention to more neutral or adaptive stimuli. The idea is that shifting attention away from negative attention bias may improve depressive symptoms.83 Therefore, in the above-mentioned study, participants with elevated depressive symptoms [based on Center for Epidemiologic Studies – Depression Scale (CES-D) scores] were randomized to undergo ABM training and augmentative t-PBM at the right forehead, left forehead, or sham. A repeat session of ABM and t-PBM was held 48 hrs later and CES-D scales were repeated at 1- and 2-week follow-ups. Each t-PBM treatment consisted of 8 consecutive minute-long applications, with 4 mins devoted to the medial region and 4 mins devoted to the lateral region of the forehead (left or right, depending on randomization). A
At baseline, this patient had a low mood and irritability, and 60J/cm² dose. The authors found that CES-D scores decreased significantly each week. Further, for participants who were responsive to ABM, t-PBM applied to the right forehead only yielded greater reduction in depressive symptoms.

The ELATED-2 Pilot aimed to test the therapeutic benefit of t-PBM in patients with unipolar MDD. Twenty-one patients with at least moderate depression were randomized and 13 subjects completed 8 weeks of twice weekly t-PBM NIR treatment (or sham) with the Omnilux New U light-emitting diode (Photomedex, Inc., Montgomeryville, PA). During each session, light at a wavelength of 823nm was used to irradiate the dorsolateral prefrontal cortex at the F3 and F4 EEG placement sites, bilaterally. While sessions started off at 20 mins, the study clinician had the option to adjust the duration of light exposure after completion of weeks 3 and 5 to 25 and 30 mins. These adjustments increased the fluence from 40J/cm² to 50J/cm² and 60J/cm², respectively. Compared to the sham group, those who underwent treatment with t-PBM had a significantly greater mean change in HAM-D₁₇ score. Response and remission occurred in 50% of the subjects in the NIR arm. Comparatively, 27% of the sham group achieved response and 18% achieved remission.

In addition to the above-mentioned studies, there have been two case reports detailing the effects of longer-term repeated administrations of t-PBM on depressive symptoms. In the first, one male patient received 20 NIR treatments over the course of 4 months, using a class IV laser (Diowave 810, West Palm Beach, FL, USA; power density range 55 to 81 J/cm²). At baseline, this patient had a low mood and irritability, in addition to several other neurological and cognitive findings. Following treatment, depression, mood dysregulation, anxiety, and irritability improved. As part of his initial work up, the patient received a SPECT scan, which was repeated 2 months after completion of NIR treatments. In the post-treatment scan, areas of statistically significant change included the bilateral frontal cortices and the bilateral temporal cortices. In the second case report, a 76-year-old Caucasian female, who carried diagnoses of MDD with “anxious distress”, hypertrophic obstructive cardiomyopathy, and Takotsubo cardiomyopathy, underwent NIR t-PBM for a total of 31 months. Over the course of therapy, the patient performed weekly self-report assessments using the Quick Inventory of Depressive Symptomatology Self-Report version (QIDS-SR16) and the Anxiety Symptoms Questionnaire (ASQ). Interestingly, she received both intranasal PBM (i-PBM) and transcranial (t-PBM), alone and in combination at different points. Initially, she only underwent treatments with i-PBM (Vielight light-emitting diode, wavelength 810nm, peak irradiance, 14.2mW/cm², average fluence 10.65J/cm², 25 mins per nostril). The frequency of treatments was progressively increased from twice a week to twice daily. 22 months after starting i-PBM, t-PBM was added [Omnilux New U device (LED), at EEG sites F3, F4, or both, twice per week for 25 mins]. t-PBM parameters were wavelength of 830nm, irradiance of 33.2mW/cm², and fluence of 49.8J/cm². Five months later, the t-PBM treatment site was switched to Fpz and the length of sessions was increased to 30 mins. With these adjustments, fluence increased to 59.8J/cm². The patient’s depressive symptoms only improved under the i-PBM plus t-PBM at site Fpz condition. Anxiety symptoms, on the other hand, steadily improved with the initiation of i-PBM, as well as the combination of i-PBM and t-PBM.

Comparison Of Animal And Clinical Studies
Several differences can be noted between the animal and clinical studies presented here. For one, almost all animal studies reviewed used laser devices. One used an infrared emitter and none of the eight studies used an LED device. Since rodent skulls are thinner than human skulls, NIR light can more easily penetrate the animal cortex and even subcortical structures. Therefore, the rodent and human studies may not be targeting the exact same cortical brain structures. Further, as is usually the case in initial pilot studies, the clinical trials were less well-controlled than the animal studies. In those reviewed earlier, several patient populations had co-morbid neuropsychiatric conditions, making it more difficult to measure antidepressant effects precisely. There was also some variability of the treatment paradigms (number of sessions, physical characteristics of the t-PBM devices) within the clinical trials themselves, complicating further a comparison. Lastly, the clinical studies used different measurements of depression (HAM-D, BDI, QIDS-SR, CES-D), making it challenging to compare patient populations as a whole.

Systemic PBM Clinical Trials
Although this is outside of the scope of this review, there is some evidence that PBM applied peripherally, not just
transcranially, may have an effect in attenuating depressive symptoms. The studies reported are small and include a variety of treatment strategies.\textsuperscript{87–90} Most importantly, there is no clear mechanism proposed explaining the effect of peripheral PBM on the brain.

Safety And Tolerability
In the studies reviewed earlier, t-PBM was found to be relatively safe and well-tolerated. Of note, not all trials reported on adverse effects and safety data were frequently only assessed in the short term. Nonetheless, very few adverse effects were reported. Headaches were reported in three separate studies.\textsuperscript{81,84,86} Other potential side effects related to the active treatment mode were fatigue, localized skin warming, irritability, insomnia, illusions (i.e., “seeing vivid colors” or “tasting from an ashtray”), and abdominal bloating.\textsuperscript{81,84} Even larger studies of t-PBM in post-stroke patients, including a pooled sample of 1410 subjects, showed no significant difference in serious adverse effects or mortality between treatment and control groups.\textsuperscript{91–94}

Discussion Of Optimal t-PBM Parameters
In this paper, we have reviewed the relevant basic and clinical studies on t-PBM for depression. Overall, the data are intriguing and open the door to a new treatment modality that may benefit a large cohort of patients. Though this field is promising, the clinical applications of this modality are still in the early stages and many questions remain.

For one, is an LED device sufficient for the delivery of therapeutic PBM? Lasers are currently the gold standard, but as Heiskanen and Hamblin (2018) have pointed out, LEDs cover more area at once, are less expensive, and are more readily used at home.\textsuperscript{95} In the first section of this paper, we discussed the relative lack of penetrance of light energy when delivered via LED, compared to lasers.\textsuperscript{12} One of the main reasons for this is likely coherence. Lasers have greater coherence of light compared to LED, by definition. Some have argued for the importance of coherent light, particularly when it comes to penetrating bulk tissue and providing therapeutic benefit.\textsuperscript{96} Others have shown that coherence of laser light is partially lost when fluid flows through tissue.\textsuperscript{97}

There have been some clinical studies comparing lasers and LED light sources directly, but they involve NIR administration to other tissues and do not address the LED brain penetration concerns. In one small randomized, placebo-controlled, double-blind cross-over study, eight volleyball players had their rectus femoris muscle pretreated with either an active LED cluster-probe (660/850 nm, 10/30 mW), a single-diode laser (810-nm 200-mW) or a placebo cluster-probe. After a standardized exercise test, it was found that the active LED group had significantly decreased creatinine kinase levels compared to the two other groups. Notably, the spot size and total energy delivered per muscle differed between the two active groups. Therefore, little can be concluded from this study about the effectiveness of laser vs LED t-PBM. On the other hand, in a near-infrared photoimmunotherapy study comparing LED and lasers in cell cultures and grafted tumors, lasers yielded better therapeutic results, in both in vitro and in vivo models.\textsuperscript{99} Though these studies are helpful, they do not involve transcranial application of PBM or the population of interest. In the clinical studies and case reports reviewed earlier, 4 out of 10 used LEDs. While it is tempting to generalize the clinical results of LEDs and lasers based on the current literature, there are too many differences between the patient populations, treatment paradigms, device settings, and brain regions targeted across these studies to come to definitive conclusions at this time. Since lasers remain the gold standard, we believe that future studies are needed to first prove conclusively the effectiveness of laser devices and then to secondly compare directly lasers and LED devices in the same patient population. If LED devices do prove to be effective, we must also consider a different mechanism of action, since, as discussed, LEDs might not provide sufficient irradiance in transcranial administration for the postulated mitochondrial enhancement in brain cells.

Another key parameter of t-PBM is whether the laser light is administered as continuous (CW) or pulsed wave (PW). While the animal and clinical literature presented here differ in this respect, most of the current data involved CW administration. Only one basic research study\textsuperscript{76} and one case report\textsuperscript{86} utilized both modalities. This begs the question: does it matter which mode is used and is one better than the other? While a complete analysis of this issue is beyond the scope of this review, there are a few key points to consider. In their 2010 review, Hashmi et al argue that pulsed lasers cause less heating, which is beneficial when higher power is needed to reach deeper layers of tissue.\textsuperscript{100} Because there is a potential ability to use higher power and cause less collateral damage, pulsing could potentially be safer and more effective, but this is a theoretical insight that would need to be proven in head-to-head studies. The few studies comparing
the two modalities directly seem to suggest an advantage for PW. A study on laser t-PBM in a stroke model of rabbits showed improvement at 6 hrs post-embolization with PW, but not CW.\textsuperscript{101} On the other hand, when treatment was applied at 12 hrs post-embolization, no statistically significant improvement was seen with either setting. In an earlier study using the same rabbits model for stroke, PW leads to a greater increase in ATP production post-embolization than CW.\textsuperscript{102} Further, in a study comparing both power densities and frequencies (continuous and pulsed) in a rat model, PW produced much less heating and led to no tissue damage at the highest power tested (750mW/cm\textsuperscript{2}).\textsuperscript{103} In contrast, both neurological deficits and histopathological damage were seen when CW was used at the same power. The authors attributed the damage to production of heat. Interestingly, some have shown better outcomes when the two are combined.\textsuperscript{104} Overall, PW t-PBM may be safer and more effective, but the most appropriate frequency of pulsing remains up for debate,\textsuperscript{100} which will require more exploratory studies with PW t-PBM.

As can be seen in the study summaries presented in Tables 1 and 2, both preclinical and clinical studies have used a wide spectrum of t-PBM parameters. While most of them appear to be safe, the studies are difficult to compare in terms of efficacy, and we can only speculate what the optimal treatment parameters for depression might be. To review, the penetration of t-PBM is greatly limited by hair, scalp, skull, and other overlying soft tissue. Skin color likely effects the level of attenuation as well,\textsuperscript{82} though only one of the trials accounted for skin tone.\textsuperscript{82} Despite these limitations, treatment may be optimized by using a laser device, NIR light in the 808–835nm range, higher power, and possibly pulsed wave (which may reduce brain heating for a given maximal irradiance). Of course, this must be balanced with the safety and tolerability of the treatment. In their study of 39 patients, Henderson and Morries (2017) utilized a power range of 8–15W and reported few adverse events, demonstrating that higher powers can be used safely.\textsuperscript{81} On the other hand, their earlier study demonstrated a more substantial temperature change in the brain with higher power (15W).\textsuperscript{12} The most effective power for treatment of depression is currently unknown, given the small breadth of clinical trials. Additionally, in terms of targetable regions, we may be limited to the prefrontal cortex, as patients are unlikely to comply with shaving their hair for the duration of treatment (which would be required for targeting temporal or parietal brain areas).

**Conclusion**

In conclusion, the studies reviewed here provide strong evidence for the mechanism of t-PBM (increasing mitochondrial energy production and increasing regional blood flow). The downstream effects of increased ATP production include not only increased cellular energy but also potentially increases in intercellular signaling.\textsuperscript{106}

The animal and human studies reviewed are supportive of a likely t-PBM effect on depression. These studies have significant limitations. Both animal and human studies have used a variety of t-PBM parameters and settings. For example, studies used different radiation power, different wavelengths, continuous vs pulsed light, acute vs chronic treatment, and irradiation of the entire cortex vs prefrontal area. It is possible that a specific intensity of t-PBM radiation may be required for clinical efficacy; this may explain inconsistencies in the literature. Only one study controlled for skin color, although differences in skin color can theoretically impact level of light absorption and the eventual dose delivered to the brain.\textsuperscript{82} However, despite these limitations, the data support a likely effect of t-PBM in MDD and highlights the need for large confirmatory studies for t-PBM as a novel, likely safe and easy-to-administer antidepressant treatment. A study comparing the different t-PBM modalities to clarify the optimal antidepressant parameters is the critical next step in the development of this technology.

**Disclosure**

Over the last five years, DVI has received consulting fees from Axsome, Alkermes, Centers of Psychiatric Excellence, MyndAnalytics (CNS Response), Jazz, Lundbeck, Precision Neuroscience, Otsuka, and Sundovion; and has received research support (through his academic institutions) from Alkermes, Astra Zeneca, Brainsway, LiteCure, Neosync, Roche, and Shire. The authors report no other conflicts of interest in this work.

**References**


29. Karu T, Afanas'eva NI. Cytochrome c oxidase acts as a primary photoacceptor in cell cultures subjected to visible and near IR laser irradiation. J Photochem Photobiol B. 1995;


Askalsky and Iosifescu


88. Quah-Smith IJ, Tang WM, Russell J. Laser acupuncture for mild to moderate depression in a primary care setting—a randomised controlled trial. Acupunct Med. 2005;23(3):103–111. doi:10.1113/aim.23.3.103


